Mitochondrial Dynamics Modulation Therapy is a novel therapeutic approach targeting the mitochondrial fission/fusion machinery and mitochondrial transport to restore neuronal energy homeostasis in neurodegenerative diseases. This strategy focuses on two key molecular nodes: DRP1 (dynamin-related protein 1) for fission regulation and Miro1 (mitochondrial Rho GTPase 1) for mitochondrial transport along axons[1][2].
The fundamental premise is that neurodegenerative diseases feature disrupted mitochondrial dynamics — excessive fission or impaired fusion and defective axonal transport lead to mitochondrial dysfunction, energy crisis, and neuronal death. By pharmacologically modulating these processes, this approach aims to restore mitochondrial network integrity and neuronal survival[3][4].
DRP1 is a cytosolic GTPase that mediates mitochondrial outer membrane fission. In AD, PD, and related disorders, hyperactivated DRP1 causes excessive mitochondrial fragmentation, leading to:
DRP1 inhibitors (such as mdivi-1) have demonstrated neuroprotective effects in multiple preclinical models. The therapeutic strategy involves:
Miro1 regulates mitochondrial axonal transport by linking mitochondria to microtubule motors. In PD, pathogenic mutations in PARK15 (serine/threonine-protein kinase 15/ERN1) impair Miro1 degradation, leading to:
Miro1 knockdown or pharmacological inhibition can restore mitochondrial motility and protect dopaminergic neurons[7][8].
| Disease | Mechanism | Evidence Level |
|---|---|---|
| Alzheimer's Disease | DRP1 hyperactivation, tau-mediated DRP1 recruitment | High (postmortem brain, iPSC neurons) |
| Parkinson's Disease | Miro1 degradation failure, PINK1/Parkin pathway disruption | High (genetic link to PARK15) |
| ALS | DRP1-mediated mitochondrial fragmentation in motor neurons | Moderate (preclinical models) |
| FTLD | DRP1 dysregulation in frontotemporal neurons | Moderate |
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 8 | Novel target class not yet in clinical trials for neurodegeneration |
| Mechanistic Rationale | 9 | Strong genetic and biochemical evidence linking mitochondrial dynamics to neurodegeneration |
| Root-Cause Coverage | 8 | Addresses fundamental energy crisis common to all neurodegenerative diseases |
| Delivery Feasibility | 7 | Small molecule inhibitors exist; brain penetration needs optimization |
| Safety Plausibility | 6 | Off-target effects possible; temporal modulation reduces risk |
| Combinability | 9 | Strong synergy with mitophagy inducers, TFEB activators, and NAD+ boosters |
| Biomarker Availability | 7 | Mitochondrial morphology in fibroblasts; phospho-DRP1 in CSF |
| De-risking Path | 7 | iPSC-derived neurons enable patient-specific validation |
| Multi-disease Potential | 9 | Broad applicability across AD, PD, ALS, and aging |
| Patient Impact | 8 | Addresses fundamental energy failure underlying cognitive and motor decline |
Total Score: 78/100
Phase 1 (Weeks 1-4): Low-dose DRP1 modulator to assess tolerability
Phase 2 (Weeks 5-12): Escalation to therapeutic dose with mitochondrial morphology monitoring
Phase 3 (Maintenance): Intermittent dosing to avoid complete fission blockade
Complete DRP1 inhibition may impair mitophagy by blocking fission required for mitochondrial turnover.
Mitigation: Use intermittent dosing or combine with mitophagy inducers.
DRP1 has structural homologs (dynamin 1, dynamin 2) that could be affected.
Mitigation: Develop isoform-selective inhibitors; use templated dosing.
Cardiac muscle requires controlled fission/fusion balance.
Mitigation: Prioritize CNS-selective compounds; cardiac monitoring in early trials.
Youle RJ, van der Bliek AM. Mitochondrial fission, fusion, and stress. Science. 2012. ↩︎
Sheng ZH, Cai Q. Mitochondrial transport in neurons: impact on synaptic homeostasis and neurodegeneration. Nature Reviews Neuroscience. 2012. ↩︎
Knott AB, Perkins G, Schwarzenbacher R, Bossy-Wetzel E. Mitochondrial fragmentation in neurodegeneration. Nature Reviews Neuroscience. 2008. ↩︎
Itoh K, Nakamura K, Iijima M, Sesaki H. Mitochondrial dynamics in neurodegeneration. Trends in Cell Biology. 2013. ↩︎
Reddy PH, Reddy TP, Manczak M, et al. Dynamin-related protein 1 and mitochondrial fragmentation in neurodegenerative diseases. Brain Research Reviews. 2011. ↩︎
Wang X, Su B, Lee HG, et al. Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. Journal of Neuroscience. 2009. ↩︎
Wang X, Winter D, Ashrafi G, et al. PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility. Cell. 2011. ↩︎
Liu S, Sawada T, Lee S, et al. Parkinson's disease-associated kinase PINK1 regulates Miro protein level and axonal transport of mitochondria. PLoS Genetics. 2012. ↩︎
Zhang L, Zhang S, Yao J, et al. Neuroprotection of mdivi-1 in Aβ-induced cognitive deficits via inhibiting mitochondrial fission. Neuropharmacology. 2015. ↩︎
Filichia E, Shen H, Zhou X, et al. Inhibition of mitochondrial fragmentation improves dopaminergic neuron survival through regulating SUMOylation. Experimental Neurology. 2015. ↩︎
Manczak M, Calkins MJ, Reddy PH. Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial proteins Drp1 and Aβ in Alzheimer's disease neurons. Human Molecular Genetics. 2011. ↩︎
Wang X, Petrie TG, Liu Y, et al. Parkinson's disease-associated DJ-1 regulates mtDNA maintenance and mitochondrial biogenesis. Human Molecular Genetics. 2012. ↩︎
Russo I, Bubacco L, Greggio E. Miro1 and mitochondrial dysfunction in Parkinson's disease. Neurobiology of Disease. 2020. ↩︎
Zhang J, Wang X, Tian Q, et al. The PINK1 Parkin pathway is activated by SERAC1 deficiency in mitochondrial disease. Brain. 2023. ↩︎